Tarsus Pharmaceuticals, Inc. TARS Finite Lived Intangible Assets Amortization Expense After Year Five
Finite Lived Intangible Assets Amortization Expense After Year Five at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s finite lived intangible assets amortization expense after year five.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s finite lived intangible assets amortization expense after year five?
- Tarsus Pharmaceuticals, Inc. (TARS) reported finite lived intangible assets amortization expense after year five of $2.56M in Q4 2025.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s finite lived intangible assets amortization expense after year five?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s finite lived intangible assets amortization expense after year five has grown at a 17.1% compound annual growth rate (CAGR), from $1.87M to $2.56M.